The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression
Abstract
IL-6 is known to be an important pro- and anti-inflammatory cytokine, which is up-regulated during sepsis. Our previous work has suggested a role for IL-6 in the up-regulation of C5aR in sepsis. We reported earlier that interception of C5a or C5aR results in improved outcomes in experimental sepsis. Using the cecal ligation/puncture (CLP) model in mice, we now demonstrate that treatment with anti-IL-6 Ab (anti-IL-6) results in significantly improved survival, dependent on the amount of Ab infused. CLP animals showed significantly increased binding of 125I-labeled anti-C5aR to organs when compared to either control mice at 0 h or CLP animals infused with normal rabbit 125I-labeled IgG. Binding of 125I-labeled anti-C5aR to lung, liver, kidney, and heart was significantly decreased in anti-IL-6-treated animals 6 h after CLP. RT-PCR experiments with mRNA isolated from various organs obtained 3, 6, and 12 h after CLP demonstrated increased C5aR mRNA expression during the onset of sepsis, which was greatly suppressed in CLP mice treated with anti-IL-6. These data suggest that IL-6 plays an important role in the increased expression of C5aR in lung, liver, kidney, and heart during the development of sepsis in mice and that interception of IL-6 leads to reduced expression of C5aR and improved survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Starnes, H. F., Pearce, M. K., Tewari, A., Yim, J. H., Zou, J. C., & Abrams, J. S. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.12.4185 · Cited by 322
RetractedHaine, M. M.-L., & Meeùs, N. (1986) · Cited by 3,464
Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139 · cited 1×
“I nterleukin-6 is a 212-aa polypeptide (1) known to have a variety of biological effects.”
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“It has been reported that IL-6 knockout mice do not show improved survival in CLP-induced sepsis (39) and that they suffer from impaired immune and acute-phase responses (40).”
Gauldie, J., Richards, C., Harnish, D., Lansdorp, P., & Baumann, H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7251 · Cited by 1,635
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNβ 2) Receptor
Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T., & Kishimoto, T. (1988) · Science · doi:10.1126/science.3136546 · Cited by 1,060
Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome
Casey, L. C., Balk, R. A., & Bone, R. C. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-8-199310150-00001 · Cited by 1,041
Cited by
Cytokine storm and sepsis disease pathogenesis
Chousterman, B. G., Swirski, F. K., & Weber, G. F. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0639-8 · Cited by 1,330
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome
Bhatia, M., & Moochhala, S. (2004) · The Journal of Pathology · doi:10.1002/path.1491 · Cited by 1,095
Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?
Dejager, L., Pinheiro, I., Dejonckheere, E., & Libert, C. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.01.001 · Cited by 784
Novel strategies for the treatment of sepsis
Riedemann, N. C., Guo, R.-F., & Ward, P. A. (2003) · Nature Medicine · doi:10.1038/nm0503-517 · Cited by 773
Self-citationImmunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
Systemic inflammation after trauma
Lenz, A., Franklin, G. A., & Cheadle, W. G. (2007) · Injury · doi:10.1016/j.injury.2007.10.003 · Cited by 600
Pleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533
Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
Carvelli, J., Demaria, O., Vély, F., Batista, L., Chouaki Benmansour, N., Fares, J., Carpentier, S., Thibult, M.-L., Morel, A., Remark, R., et al. (2020) · Nature · doi:10.1038/s41586-020-2600-6 · Cited by 526
The dark side of C5a in sepsis
Ward, P. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1269 · Cited by 422
Self-citationInterleukin (IL-6) Immunotherapy
Tanaka, T., Narazaki, M., & Kishimoto, T. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028456 · Cited by 407
The disconnect between animal models of sepsis and human sepsis
Rittirsch, D., Hoesel, L. M., & Ward, P. A. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806542 · Cited by 406
Self-citationInterplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Critical Role of IL-17RA in Immunopathology of Influenza Infection
Crowe, C. R., Chen, K., Pociask, D. A., Alcorn, J. F., Krivich, C., Enelow, R. I., Ross, T. M., Witztum, J. L., & Kolls, J. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900995 · Cited by 349
Day, Y.-J., Huang, L., Ye, H., Linden, J., & Okusa, M. D. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00378.2004 · Cited by 331
The dynamics of acute inflammation
Kumar, R., Clermont, G., Vodovotz, Y., & Chow, C. C. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.04.044 · Cited by 322
Interleukin-6 and Cardiovascular Diseases
Kanda, T., & Takahashi, T. (2004) · Japanese Heart Journal · doi:10.1536/jhj.45.183 · Cited by 265
ACUTE PANCREATITIS: MODELS, MARKERS, AND MEDIATORS
Granger, J., & Remick, D. (2005) · Shock · doi:10.1097/01.shk.0000191413.94461.b0 · Cited by 260
Pharmacologic Treatment of Acute Kidney Injury: Why Drugs Haven’t Worked and What Is on the Horizon
Jo, S. K., Rosner, M. H., & Okusa, M. D. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03280906 · Cited by 252
Kwan, W.-H., van der Touw, W., Paz-Artal, E., Li, M. O., & Heeger, P. S. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121525 · Cited by 215
“…inhib iting T reg cell function (Pasare and Medzhitov, 2003; Hu et al., 2011; Peng et al., 2006; Zhou et al., 2006), and that the IL6–mediated effects are linked to C5aR in other cell types (Riedemann et al., 2003, 2004), thereby providing additional associative evidence in support of this concept.”
BackgroundBarkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318211ff56 · Cited by 169
Sutherland, R. E., Olsen, J. S., McKinstry, A., Villalta, S. A., & Wolters, P. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5598 · Cited by 155
“IL-6 is a pleiotropic cytokine (15) that, depending on the infection model, has been reported to have a beneficial (12, 16, 51, 52), detrimental (18), or neutral (19, 53) effect on survival of bacterial infection.”
BackgroundIL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers
Zhu, S., Ashok, M., Li, J., Li, W., Yang, H., Wang, P., Tracey, K. J., Sama, A. E., & Wang, H. (2009) · Molecular Medicine · doi:10.2119/molmed.2009.00062 · Cited by 109
Siderophores: More than Stealing Iron
Behnsen, J., & Raffatellu, M. (2016) · mBio · doi:10.1128/mbio.01906-16 · Cited by 79
Ibrahim, Y. F., Moussa, R. A., Bayoumi, A. M. A., & Ahmed, A.-S. F. (2020) · Inflammopharmacology · doi:10.1007/s10787-019-00628-y · Cited by 75
Nuclear Factor-κB p50 Limits Inflammation and Prevents Lung Injury during Escherichia coli Pneumonia
Mizgerd, J. P., Lupa, M. M., Kogan, M. S., Warren, H. B., Kobzik, L., & Topulos, G. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200303-412oc · Cited by 66
Tyrosine kinase inhibitor tyrphostin AG490 reduces liver injury in LPS-induced shock
Gyurkovska, V., & Ivanovska, N. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.01.045 · Cited by 11
Klein, C., Medina, E., Sander, L., Dierssen, U., Roskams, T., Mueller, W., Trautwein, C., & Goldmann, O. (2007) · The Journal of Infectious Diseases · doi:10.1086/520090 · Cited by 11
Metadata
- Authors
- Riedemann, N. C., Neff, T. A., Guo, R.-F., Bernacki, K. D., Laudes, I. J., Sarma, J. V., Lambris, J. D., & Ward, P. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-01
- Volume
- 170
- Issue
- 1
- Pages
- 503-507
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1569271652
- Cited by
- 330
- References
- 40
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.